- Previous Close
3.7900 - Open
3.7900 - Bid 3.8600 x --
- Ask 3.7400 x --
- Day's Range
3.7900 - 3.8600 - 52 Week Range
3.2200 - 7.7100 - Volume
17,097 - Avg. Volume
34,472 - Market Cap (intraday)
292.472M - Beta (5Y Monthly) 1.11
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0400 - Earnings Date May 28, 2025 - Jun 2, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Transgene Biotek Limited, a biotechnology company, provides research and development services for bulk drugs in India. It offers oncology drugs, oral drug delivery, and biogenerics, as well as HIV and multiple sclerosis drugs. The company provides TrabiDHA for use in health food, baby food/formula, health supplement, and chicken and animal feed markets; Tacrolimus, a drug that suppresses the immune system and is used to prevent rejection of transplanted organs; and Orlistat (tetrahydrolipstatin), a lipase inhibitor that blocks about one-third of intestinal fat absorption. The company was incorporated in 1990 and is based in Sangareddy, India.
www.transgenebiotek.comRecent News: TRABI.BO
View MorePerformance Overview: TRABI.BO
Trailing total returns as of 4/17/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TRABI.BO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TRABI.BO
View MoreValuation Measures
Market Cap
292.47M
Enterprise Value
431.95M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
127.61
Price/Book (mrq)
2.70
Enterprise Value/Revenue
188.46
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-99.44%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
2.29M
Net Income Avi to Common (ttm)
-2.28M
Diluted EPS (ttm)
-0.0400
Balance Sheet and Cash Flow
Total Cash (mrq)
113k
Total Debt/Equity (mrq)
128.87%
Levered Free Cash Flow (ttm)
--